Search

everythinglearnresearchcommunity

for

Search:↓

Quercetin effectively treated and prevented hair loss in mice.

Natural volatiles and essential oils have health benefits and can enhance the effects of some medicines, but more research is needed to understand how they work and their possible side effects.

Middle-aged women in Iran are most affected by primary cicatricial alopecia, especially discoid lupus erythematous.

Certain natural and synthetic compounds may help treat inflammatory skin diseases by targeting a specific signaling pathway.

Synthetic antioxidants are effective, cheap, and stable, with some like zinc and cholecalciferol reducing child and cancer deaths, but the safety of additives like BHA, BHT, TBHQ, and PEG needs more research.

Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.

Hormonal imbalances in Polycystic Ovarian Syndrome (PCOS) might trigger a rare skin disorder called Confluent and Reticulated Papillomatosis (CRP), so dermatologists should consider checking for PCOS in CRP patients.

Collagen from tilapia scales may improve hair and skin health by reducing stress and inflammation and encouraging hair growth.

Microneedles are promising for long-acting drug delivery and can improve patient compliance, but more data is needed to confirm their effectiveness.

Hormones like androgens, estrogen, thyroid hormones, and stress hormones can contribute to hair loss, and treatments target these hormonal imbalances.

Many people in Saudi Arabia experienced hair loss after COVID-19, especially women, those treated with antivirals, and those with a history of hair shedding.

Alopecia areata needs more recognition and better treatment access in Latin America to improve patient care and outcomes.

Two young cats with a severe ear and skin condition improved with immune system-targeting treatments.

Topical DPCP is somewhat effective for hair loss in alopecia areata, but more research is needed.

Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.

Congenital alopecia areata may have genetic links and topical corticosteroids are an effective treatment.

Topical drugs and near-infrared light therapy show potential for treating alopecia.

Topical immunotherapy can treat alopecia areata, but its effectiveness varies and the exact mechanism is unclear.

Squaric acid dibutylester can cause severe skin reactions in people with allergies.

Contact immunotherapy can cause vitiligo in patients with autoimmune conditions.

Alopecia Areata is an autoimmune condition often starting before age 20, with varied treatment success and a need for personalized treatment plans.

Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.

Hair loss in teenagers is hard to treat and lacks a cure, with some treatments available depending on the type of hair loss.

The document concludes that more research is needed to understand and treat Beard Alopecia Areata due to limited current knowledge and evidence.

Some treatments can stabilize Frontal Fibrosing Alopecia, but more research is needed to find effective treatments, and hair transplants often fail.

Various treatments exist for alopecia areata, but none are completely satisfactory; choice depends on age, disease extent, and preference.

The document says that common skin conditions in adult women can be treated effectively, with acne being the most common and early-detected melanoma having a high survival rate.

Alopecia Areata is an unpredictable autoimmune hair loss condition with limited and variable treatment effectiveness.

The document concludes that low-dose acne treatment is most suitable for moderate acne, with high patient satisfaction and low relapse rates.

Some hair loss disorders cause permanent loss due to scarring, and treatments like steroids don't always work well.